Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 st1\:*behavior:url(#ieooui) /* Style Definitions */ table
Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 st1\:*behavior:url(#ieooui) /* Style Definitions */ table.MsoNormalTable mso-style-name:”Table Normal”; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:””; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:11.0pt; font-family:”Calibri”,”sans-serif”; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:”Times New Roman”; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:”Times New Roman”; mso-bidi-theme-font:minor-bidi; Vardenafil (INN) is a PDE5 inhibitor used for treating impotence (erectile dysfunction) that is sold under the trade name Levitra Do you know what exactly is special about Levitra? It is Vardenafil hydrochloride, a strong molecule with a weight of 488.604 g/mol. As a PDE5 inhibitor, Vardenafil is closely related in both function and marketing to Sildenafil and Tadalafil though; it has a comparatively short effective time with less instances of failure. Those who have Levitra experience, have pointed out that unlike other ED pills, Levitra has worked for them on the very first attempt. Vardenafil was co-marketed by Bayer Pharmaceuticals, GSK, and SP under the trade name Levitra. As of 2005, the co-promotion rights of GSK on Levitra have been returned to Bayer in many markets outside the U.S. In Italy, Bayer sells vardenafil as Levitra and GSK sells it as Vivanza, thus, because of European Union trade rules, parallel imports might result in Vivanza sold next to Levitra in the EU. The main ingredient of Levitra, Vardenafil hydrochloride is a potent molecule which requires smaller dosage to get into full action....
Read More
Comentarios recientes